Search

Displaying results 9191 - 9200 of 10000 in total
  1. Drug

    123I-iodometomidate

    go.drugbank.com/drugs/DB13021
    Investigational

    123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).

  2. Drug

    Clorindione

    go.drugbank.com/drugs/DB13275
    Experimental

    Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans.

  3. Drug

    IQP-0528

    go.drugbank.com/drugs/DB14888
    Investigational

    IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).

  4. Drug

    Suvratoxumab

    go.drugbank.com/drugs/DB15172
    Investigational

    Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).

  5. Drug

    Florasulam

    go.drugbank.com/drugs/DB15316
    Experimental

    Florasulam is under investigation in clinical trial NCT01193465 (Temperature and Humidity Among Different Anesthesia Work-station).

  6. Drug

    Thallium Tl-201

    go.drugbank.com/drugs/DB15361
    Investigational

    Thallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).

  7. Drug

    Rivenprost

    go.drugbank.com/drugs/DB16315
    Investigational

    Rivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).

  8. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

    Synonyms: 5’-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-spdA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3’
  9. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  10. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.